David A. Siegel Sage Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 198,799 shares of SAGE stock, worth $1.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

198,799

Previous 324,999 38.83%

Holding current value

$1.73 Million

Previous $2.58 Million 29.81%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.38 - $9.3 $805,156 - $1.17 Million	-126,200 Reduced 38.83%	198,799 $1.81 Million
Q1 2025 May 15, 2025	BUY	$5.55 - $8.66 $1.15 Million - $1.79 Million	207,200 Added 175.89%	324,999 $2.58 Million
Q4 2024 Feb 14, 2025	SELL	$4.78 - $8.57 $12,428 - $22,282	-2,600 Reduced 2.16%	117,799 $639,000
Q3 2024 Nov 14, 2024	SELL	$7.02 - $13.08 $212,004 - $395,016	-30,200 Reduced 20.05%	120,399 $868,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $1.31 Million - $2.22 Million	124,099 Added 468.3%	150,599 $1.64 Million
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $20,482 - $29,645	1,100 Added 4.33%	26,500 $496,000
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $434,340 - $565,404	25,400 New	25,400 $550,000
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $3.57 Million - $5.22 Million	-87,700 Reduced 66.54%	44,098 $2.07 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $913,115 - $1.14 Million	-24,500 Reduced 15.68%	131,798 $5.53 Million
Q4 2022 Feb 14, 2023	BUY	$32.2 - $43.61 $676,200 - $915,810	21,000 Added 15.52%	156,298 $5.96 Million
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $2.19 Million - $2.93 Million	67,700 Added 100.15%	135,298 $5.3 Million
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $731,976 - $1.01 Million	26,598 Added 64.87%	67,598 $2.18 Million
Q1 2022 May 16, 2022	SELL	$30.71 - $45.71 $128,982 - $191,982	-4,200 Reduced 9.29%	41,000 $1.36 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $122,298 - $155,463	-3,300 Reduced 6.8%	45,200 $1.92 Million
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $7.22 Million - $10.3 Million	-179,299 Reduced 78.71%	48,500 $2.15 Million
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $7.4 Million - $10.7 Million	-134,900 Reduced 37.19%	227,799 $12.9 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $4.18 Million - $5.72 Million	-59,100 Reduced 14.01%	362,699 $27.1 Million
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $6.4 Million - $9.76 Million	-109,600 Reduced 20.62%	421,799 $36.5 Million
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $8.25 Million - $12.5 Million	-200,600 Reduced 27.4%	531,399 $32.5 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $7.31 Million - $12.2 Million	281,800 Added 62.59%	731,999 $30.4 Million
Q1 2020 May 15, 2020	BUY	$26.15 - $77.24 $11.8 Million - $34.8 Million	450,199 New	450,199 $12.9 Million
Q4 2019 Feb 14, 2020	SELL	$60.18 - $154.77 $361,080 - $928,620	-6,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $841,740 - $1.14 Million	6,000 New	6,000 $842,000
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $1.74 Million - $2.13 Million	-12,600 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $2.98 Million - $3.73 Million	-21,200 Reduced 62.72%	12,600 $1.97 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $3.18 Million - $4.02 Million	20,900 Added 162.02%	33,800 $5.44 Million
Q4 2017 Feb 14, 2018	BUY	$60.72 - $167.34 $783,288 - $2.16 Million	12,900	12,900 $2.13 Million

Others Institutions Holding SAGE

# of Institutions

215

Shares Held

50.1M

Call Options Held

790K

Put Options Held

440K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $516M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account